Glaukos Corp (NYSE:GKOS) was the target of some unusual options trading activity on Monday. Investors bought 3,425 call options on the company. This represents an increase of approximately 5,608% compared to the typical volume of 60 call options.
In other Glaukos news, CFO Joseph E. Gilliam sold 3,750 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $68.50, for a total transaction of $256,875.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 15,512 shares of company stock valued at $990,672 in the last 90 days. 8.70% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of GKOS. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Glaukos by 9.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,274 shares of the medical instruments supplier’s stock valued at $171,000 after buying an additional 201 shares during the period. Lisanti Capital Growth LLC grew its position in Glaukos by 1.1% during the second quarter. Lisanti Capital Growth LLC now owns 31,770 shares of the medical instruments supplier’s stock valued at $2,395,000 after buying an additional 340 shares during the period. JPMorgan Chase & Co. grew its position in Glaukos by 0.9% during the second quarter. JPMorgan Chase & Co. now owns 46,720 shares of the medical instruments supplier’s stock valued at $3,544,000 after buying an additional 406 shares during the period. NEXT Financial Group Inc grew its position in Glaukos by 73.7% during the second quarter. NEXT Financial Group Inc now owns 1,129 shares of the medical instruments supplier’s stock valued at $85,000 after buying an additional 479 shares during the period. Finally, Harvest Fund Management Co. Ltd bought a new position in Glaukos during the second quarter valued at about $39,000. Hedge funds and other institutional investors own 96.56% of the company’s stock.
NYSE GKOS opened at $64.26 on Wednesday. Glaukos has a 1 year low of $50.60 and a 1 year high of $84.65. The company has a debt-to-equity ratio of 0.42, a current ratio of 6.32 and a quick ratio of 5.94. The firm has a market cap of $2.26 billion, a price-to-earnings ratio of -173.68 and a beta of 1.68. The company has a fifty day moving average price of $63.02 and a 200-day moving average price of $68.77.
Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.07. Glaukos had a negative net margin of 8.60% and a negative return on equity of 4.01%. The firm had revenue of $58.51 million during the quarter, compared to analyst estimates of $56.96 million. During the same quarter in the prior year, the business posted ($0.17) EPS. The business’s revenue was up 33.2% compared to the same quarter last year. On average, research analysts anticipate that Glaukos will post -0.4 EPS for the current fiscal year.
Several analysts have recently issued reports on GKOS shares. ValuEngine upgraded shares of Glaukos from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 8th. Stifel Nicolaus reduced their target price on shares of Glaukos from $73.00 to $69.00 and set a “hold” rating for the company in a research note on Thursday, November 7th. BTIG Research reiterated a “hold” rating on shares of Glaukos in a research note on Wednesday, October 30th. Bank of America lowered shares of Glaukos from a “buy” rating to an “underperform” rating and set a $67.00 target price for the company. in a research note on Monday, September 30th. Finally, JPMorgan Chase & Co. set a $90.00 target price on shares of Glaukos and gave the stock a “buy” rating in a research note on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $74.88.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.
Recommended Story: Producer Price Index (PPI)
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.